华兰疫苗：目前国内流行的流感病毒主要是甲型H3N2型，接种公司的流感疫苗能够起到有效的预防作用

Core Viewpoint - The company, Hualan Vaccine, is positioned as a leading player in the domestic influenza vaccine market, with a significant number of batches approved for distribution in 2025 [2] Group 1: Company Performance - Hualan Vaccine reported that it ranked among the top in China for the number of influenza vaccine batch approvals, with a total of 57 batches issued in the 2025 fiscal year according to public data from the China National Institute for Food and Drug Control [2] - The company is actively distributing influenza vaccines nationwide based on orders from local disease control centers, indicating a responsive supply chain to market demand [2] Group 2: Market Context - The predominant strain of influenza virus currently circulating in the domestic market is the H3N2 subtype, and the company's vaccine is effective in providing prevention against this strain [2]